Payment overview · 2025
General Payments
$1,505.89
7 reported records · 4 companies
Healthcare provider profile · identity verified
David Behar, MD
Allopathic & Osteopathic Physicians|Psychiatry & Neurology|Psychiatry · BETHLEHEM, PA · NPI 1497739916
Verified facts
What the public records show
CMS Open Payments records show David Behar, MD received $1,505.89 in general payments during 2025 across 7 reported records.
E.R. Squibb & Sons, L.L.C. accounted for 95.6% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 4 associated products.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 32 claims for Ozempic by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $1,439.49 | 95.6% | 4 | 2025 |
| Indivior Inc. | Unresolved — no canonical attribution shown | $24.91 | 1.6% | 1 | 2025 |
| Alkermes, Inc. | Unresolved — no canonical attribution shown | $23.73 | 1.6% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $17.76 | 1.2% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Consulting Fee | $1,380.00 | 1 |
| Food and Beverage | $125.89 | 6 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| COBENFY Normalized: cobenfy |
Drug | E.R. Squibb & Sons, L.L.C. | $59.49 | 3 | 2025 |
Source payment records
|
|||||
| SUBLOCADE Normalized: sublocade |
Drug | Indivior Inc. | $24.91 | 1 | 2025 |
Source payment records
|
|||||
| ARISTADA Normalized: aristada |
Drug | Alkermes, Inc. | $23.73 | 1 | 2025 |
Source payment records
|
|||||
| LYBALVI Normalized: lybalvi |
Drug | Alkermes, Inc. | $23.73 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
32 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Clozapine | Clozapine | 488 | 32 |
| Benztropine Mesylate | Benztropine Mesylate | 239 | 39 |
| Aripiprazole | Aripiprazole | 177 | 25 |
| Olanzapine | Olanzapine | 173 | 19 |
| Clonazepam | Clonazepam | 172 | 16 |
| Sertraline Hcl | Sertraline Hcl | 168 | 19 |
| Doxepin Hcl | Doxepin Hcl | 167 | 21 |
| Bupropion Xl | Bupropion Hcl | 166 | 19 |
| Lorazepam | Lorazepam | 156 | 26 |
| Duloxetine Hcl | Duloxetine Hcl | 147 | 14 |
| Risperidone | Risperidone | 138 | 15 |
| Divalproex Sodium | Divalproex Sodium | 132 | 11 |
| Fluticasone Propionate | Fluticasone Propionate | 126 | 20 |
| Gabapentin | Gabapentin | 119 | 14 |
| Invega Sustenna | Paliperidone Palmitate | 118 | 11 |
| Ziprasidone Hcl | Ziprasidone Hcl | 117 | 12 |
| Lamotrigine | Lamotrigine | 107 | 12 |
| Trazodone Hcl | Trazodone Hcl | 101 | 15 |
| Haloperidol | Haloperidol | 98 | 13 |
| Metformin Hcl | Metformin Hcl | 98 | 11 |
| Alprazolam | Alprazolam | 97 | 17 |
| Atorvastatin Calcium | Atorvastatin Calcium | 97 | 11 |
| Divalproex Sodium Er | Divalproex Sodium | 96 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 89 | 11 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 85 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 84 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 83 | 17 |
| Citalopram Hbr | Citalopram Hydrobromide | 79 | suppressed |
| Levothyroxine Sodium | Levothyroxine Sodium | 72 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 70 | suppressed |
| Prazosin Hcl | Prazosin Hcl | 70 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 68 | suppressed |
| Atomoxetine Hcl | Atomoxetine Hcl | 63 | 11 |
| Propranolol Hcl | Propranolol Hcl | 61 | suppressed |
| Vraylar | Cariprazine Hcl | 61 | suppressed |
| Lurasidone Hcl | Lurasidone Hcl | 60 | suppressed |
| Pantoprazole Sodium | Pantoprazole Sodium | 58 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 56 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 55 | suppressed |
| Autoshield Duo Pen Needle | Pen Needle,dual Safety,diabetc | 54 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 54 | 11 |
| Donepezil Hcl | Donepezil Hcl | 54 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 54 | suppressed |
| Omeprazole | Omeprazole | 53 | suppressed |
| Galantamine Hbr | Galantamine Hbr | 52 | suppressed |
| Mirtazapine | Mirtazapine | 52 | suppressed |
| Glycopyrrolate | Glycopyrrolate | 51 | suppressed |
| Lisinopril | Lisinopril | 50 | suppressed |
| Famotidine | Famotidine | 49 | suppressed |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 48 | suppressed |
| Topiramate | Topiramate | 48 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 45 | suppressed |
| Metoprolol Tartrate | Metoprolol Tartrate | 44 | suppressed |
| Temazepam | Temazepam | 44 | suppressed |
| Furosemide | Furosemide | 42 | suppressed |
| Tamsulosin Hcl | Tamsulosin Hcl | 41 | suppressed |
| Simvastatin | Simvastatin | 40 | suppressed |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 39 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 39 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 39 | suppressed |
| Trintellix | Vortioxetine Hydrobromide | 35 | suppressed |
| Fanapt | Iloperidone | 34 | suppressed |
| Asenapine Maleate | Asenapine Maleate | 33 | suppressed |
| Ibuprofen | Ibuprofen | 33 | 15 |
| Desmopressin Acetate | Desmopressin Acetate | 32 | suppressed |
| Ozempic | Semaglutide | 32 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 31 | suppressed |
| Paliperidone Er | Paliperidone | 31 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 29 | suppressed |
| Diazepam | Diazepam | 28 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 28 | suppressed |
| Austedo Xr | Deutetrabenazine | 26 | suppressed |
| Buprenorphine Hcl | Buprenorphine Hcl | 26 | suppressed |
| Norgestimate-Ethinyl Estradiol | Norgestimate-Ethinyl Estradiol | 26 | suppressed |
| Trihexyphenidyl Hcl | Trihexyphenidyl Hcl | 26 | suppressed |
| Erythromycin | Erythromycin Base | 25 | suppressed |
| Haloperidol Decanoate | Haloperidol Decanoate | 25 | suppressed |
| Latanoprost | Latanoprost | 25 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 25 | suppressed |
| Novofine Autocover | Pen Needle, Diabetic, Safety | 24 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 23 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 23 | suppressed |
| Eszopiclone | Eszopiclone | 22 | suppressed |
| Naltrexone Hcl | Naltrexone Hcl | 22 | suppressed |
| Varenicline Tartrate | Varenicline Tartrate | 22 | suppressed |
| Buprenorphine-Naloxone | Buprenorphine Hcl/Naloxone Hcl | 21 | suppressed |
| Lithium Carbonate | Lithium Carbonate | 21 | suppressed |
| Rexulti | Brexpiprazole | 21 | suppressed |
| Metoprolol Succinate | Metoprolol Succinate | 20 | suppressed |
| Naproxen | Naproxen | 20 | suppressed |
| Vilazodone Hcl | Vilazodone Hcl | 20 | suppressed |
| Fluvoxamine Maleate | Fluvoxamine Maleate | 19 | suppressed |
| Abilify Maintena | Aripiprazole | 18 | suppressed |
| Amlodipine Besylate | Amlodipine Besylate | 18 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 18 | suppressed |
| Mounjaro | Tirzepatide | 18 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 18 | suppressed |
| Trulicity | Dulaglutide | 15 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 14 | suppressed |
| Dorzolamide Hcl | Dorzolamide Hcl | 14 | suppressed |
| Vyzulta | Latanoprostene Bunod | 14 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 14 | suppressed |
| Ammonium Lactate | Ammonium Lactate | 13 | suppressed |
| Dorzolamide-Timolol | Dorzolamide Hcl/Timolol Maleat | 13 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 13 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 13 | suppressed |
| Januvia | Sitagliptin Phosphate | 13 | suppressed |
| Jardiance | Empagliflozin | 13 | suppressed |
| Lithium Carbonate Er | Lithium Carbonate | 13 | suppressed |
| Losartan Potassium | Losartan Potassium | 13 | suppressed |
| Memantine Hcl | Memantine Hcl | 13 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 13 | suppressed |
| Methylphenidate Er | Methylphenidate Hcl | 13 | suppressed |
| Novolog Flexpen | Insulin Aspart | 13 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 13 | suppressed |
| Perphenazine | Perphenazine | 13 | suppressed |
| Sulindac | Sulindac | 13 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 13 | suppressed |
| Xarelto | Rivaroxaban | 13 | suppressed |
| Belsomra | Suvorexant | 12 | suppressed |
| Calcitonin-Salmon | Calcitonin,salmon,synthetic | 12 | suppressed |
| Ingrezza | Valbenazine Tosylate | 12 | suppressed |
| Neomycin-Polymyxin-Hc | Neomycin/Polymyxin B/Hydrocort | 12 | suppressed |
| Spiriva Handihaler | Tiotropium Bromide | 12 | suppressed |
| Tri-Lo-Marzia | Norgestimate-Ethinyl Estradiol | 12 | suppressed |
| Valsartan | Valsartan | 12 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 11 | suppressed |
| Carvedilol | Carvedilol | 11 | suppressed |
| Indomethacin | Indomethacin | 11 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 11 | suppressed |
| Trifluoperazine Hcl | Trifluoperazine Hcl | 11 | suppressed |
| Trimipramine Maleate | Trimipramine Maleate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,505.89 · 7 records | E.R. Squibb & Sons, L.L.C. | ARISTADA, COBENFY, LYBALVI, SUBLOCADE | 1 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- How do you evaluate evidence when you have a financial relationship with Novo Nordisk Inc?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error